- |||||||||| ronopterin (VAS203) / Vasopharm, dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka, Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
Review, Journal: Neuroprotective and neuroregenerative drugs after severe traumatic brain injury : A (Pubmed Central) - Dec 10, 2024
Some pharmacologic attempts that appeared very promising in experimental settings have had disappointing clinical results (progesterone, cyclosporine
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka, Cesamet (nabilone) / Bausch Health, Viatris
Clinical, Retrospective data, Review, Journal: Cannabinoids Used for Medical Purposes in Children and Adolescents: A Systematic Review and Meta-Analysis. (Pubmed Central) - Nov 4, 2024
In this systematic review and meta-analysis, cannabinoids used for medical purposes in children and adolescents in RCTs were associated with an increased risk of adverse events. The findings suggest that long-term safety studies, including those exploring cannabinoid-related drug interactions and tools that improve adverse event reporting, are needed.
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Retrospective data, Review: Effect of drug therapy on nerve repair of moderate-severe traumatic brain injury: A network meta-analysis. (Pubmed Central) - Nov 22, 2022
Among these, the progesterone + vitamin D had not only a higher proportion of patients with good recovery and moderate disability but also a lower proportion of patients with severe disability and mortality. However, whether this intervention can be used for clinical promotion still needs further exploration.
- |||||||||| betahistine intranasal (AM-201) / Auris Medical, dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Journal: Oral fluid analysis to monitor recent exposure to synthetic cannabinoids in a high-risk subpopulation. (Pubmed Central) - Sep 10, 2022
The identified SCRA proved the persistence into the market of the "first-generation" JWH family into the Italian territory and the marketing of relatively new ones (AM-2201). Public health consequences represented by NPS consumption are still scarce; therefore, further studies are needed to understand the real diffusion in the population.
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Preclinical, Journal: Deficiency of autism-related Scn2a gene in mice disrupts sleep patterns and circadian rhythms. (Pubmed Central) - Apr 21, 2022
Performing a transcriptome-based compound discovery, we identified dexanabinol (HU-211), a putative glutamate receptor modulator, that can partially reverse the sleep disturbance in mice. Overall, our study reveals possible molecular and cellular mechanisms underlying Scn2a deficiency-related sleep disturbances, which may inform the development of potential pharmacogenetic interventions for the affected individuals.
- |||||||||| bortezomib / Generic mfg.
Journal: Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain. (Pubmed Central) - Feb 8, 2022
Dexanabinol failed to restore bortezomib-induced decreases in electrophysiological endpoints in rats, and it did not compromise bortezomib anti-cancer effects in U266 multiple myeloma cells and a murine xenograft model. Owing to its favorable safety profile in humans and preclinical efficacy, dexanabinol might represent a treatment option for bortezomib-induced neuropathic pain.
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska
Journal: Analysis of long non-coding RNA expression profiles in disuse osteoporosis using microarray and bioinformatics. (Pubmed Central) - Sep 2, 2021
Three bioactive compounds (scoulerine, kinetin riboside, dexanabinol) with potential therapeutic significance for DOP were obtained through the Connectivity Map (CMAP) analysis. Our study revealed a new mechanism for a lineage shift of bone marrow mesenchymal stem cells under microgravity, and linked the function of protein-coding mRNAs with ncRNAs, which may contribute to the development of new therapies for DOP.
- |||||||||| dexanabinol (ETS2101) - E / Therap, Pharmos
Clinical, P1 data, PK/PD data, Journal: Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer. (Pubmed Central) - Feb 23, 2021
Five of 24 efficacy-evaluable patients (21%) experienced stable disease with a median duration of 2 cycles (28-day cycle) as the best response. Dexanabinol administered weekly by intravenous infusion was safe and well-tolerated up to 28 mg/kg in brain cancer patients, but has limited antitumor activity in patients with brain cancer.
- |||||||||| dexanabinol (ETS2101) - E / Therap, Pharmos
Journal: Effects of cannabinoids on the development of chick embryos in ovo. (Pubmed Central) - Nov 2, 2020
We have examined the effects of the synthetic cannabinoids HU 210 and HU 211, the plant-derived cannabidiol and the endogenous cannabinoid anandamide on the viability and development of chick embryos...This study shows that exposure to plant-derived or synthetic cannabinoids during early embryonal development decreases embryonal viability. Extrapolation of data across species is of course difficult, but the data would argue against the use of cannabinoids, be it recreationally or therapeutically, during pregnancy.
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Trial completion: Dexanabinol in Patients With Brain Cancer (clinicaltrials.gov) - Jul 7, 2017
P1, N=26, Completed,
2017-DW-020) on May 24, 2017. Active, not recruiting --> Completed
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Enrollment closed, Combination therapy, Monotherapy, Metastases: A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours (clinicaltrials.gov) - Apr 6, 2016
P1, N=112, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Enrollment change: Dexanabinol in Patients With Brain Cancer (clinicaltrials.gov) - Nov 21, 2015
P1, N=26, Active, not recruiting,
Recruiting --> Active, not recruiting N=60 --> 26
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Enrollment closed: Dexanabinol in Patients With Brain Cancer (clinicaltrials.gov) - Aug 12, 2015
P1, N=60, Active, not recruiting,
N=60 --> 26 Recruiting --> Active, not recruiting
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Trial primary completion date: Dexanabinol in Patients With Brain Cancer (clinicaltrials.gov) - Jun 11, 2015
P1, N=60, Recruiting,
Active, not recruiting --> Completed Trial primary completion date: Feb 2015 --> Aug 2015
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Enrollment change: Dexanabinol in Patients With Brain Cancer (clinicaltrials.gov) - Nov 12, 2014
P1, N=60, Recruiting,
Trial primary completion date: Oct 2014 --> Jun 2015 N=24 --> 60
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Trial completion, Enrollment change, Trial primary completion date: Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects (clinicaltrials.gov) - Oct 10, 2014
P1, N=40, Completed,
N=24 --> 60 Recruiting --> Completed | N=24 --> 40 | Trial primary completion date: Apr 2014 --> Sep 2014
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Trial primary completion date: Dexanabinol in Patients With Brain Cancer (clinicaltrials.gov) - May 20, 2014
P1, N=24, Recruiting,
Recruiting --> Completed | N=24 --> 40 | Trial primary completion date: Apr 2014 --> Sep 2014 Trial primary completion date: Dec 2013 --> Dec 2014
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Trial completion date: Dexanabinol in Patients With Brain Cancer (clinicaltrials.gov) - May 20, 2014
P1, N=24, Recruiting,
Trial primary completion date: Dec 2013 --> Dec 2014 Trial completion date: Jun 2014 --> Jun 2015
- |||||||||| dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka
Enrollment open: Dexanabinol in Patients With Brain Cancer (clinicaltrials.gov) - May 16, 2013
P1, N=24, Recruiting,
Active, not recruiting --> Recruiting Active, not recruiting --> Recruiting
|
